ReviewMarine drugs2010
Marine drugs from sponge-microbe association--a review.
Review in Marine drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed.
- Global distribution of deep-sea natural products shows environmental and phylogenetic undersampling with potential for biodiscovery.Scientific reports · 2026Article
- Bioconversion of carotenoids into high-value crocins using a marine sponge carotenoid cleavage dioxygenase.The New phytologist · 2026Article
- Catechol-derived propargyl diol cyclizations with malonyl dichloride: substituent effects on the formation of macrocyclic esters and their hydrochlorinated adducts.RSC advances · 2026Article
- Review
- Discovery, biosynthesis, and bioactivities of peptidic natural products from marine sponges and sponge-associated bacteria.Natural product reports · 2025Review
- Shifting microbial communities in acidified seawaters: insights from polychaetes living in the COIntegrative zoology · 2025Article
- Tartrolon E rapidly blocks Toxoplasma gondii capacity to invade host cells.International journal for parasitology. Drugs and drug resistance · 2025Article
- Antimicrobial Metabolites Isolated from Some Marine Bacteria Associated withMicroorganisms · 2025Article
- Mini review: antimicrobial compounds produced by bacteria associated with marine invertebrates.Folia microbiologica · 2025Review
- Presence of polyketide synthases and nonribosomal peptide synthetase in culturable bacteria associated with Aplysina fulva and Aplysina caissara (Porifera).Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Progress in Preparation Technology and Functional Research On Marine Bioactive Peptides.Marine biotechnology (New York, N.Y.) · 2025Review
- An Integrated Computational Approach to Identify Potent HIV-1 Protease Inhibitors from Marine Sources.Combinatorial chemistry & high throughput screening · 2025Article
- Article
- Review
- Isolation and identification of antifungal, antibacterial and nematocide agents from marine bacillus gottheilii MSB1.BMC biotechnology · 2024Article
- Exploring the secrets of marine microorganisms: Unveiling secondary metabolites through metagenomics.Microbial biotechnology · 2024Review
- Unveiling antibiofilm potential: proteins from Priestia sp. targeting Staphylococcus aureus biofilm formation.Antonie van Leeuwenhoek · 2024Article
- Animal Microbiomes as a Source of Novel Antibiotic-Producing Strains.International journal of molecular sciences · 2023Review
- An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Alternaria alternata (SDHY01/02), a fungus associated with Lamellodysidea herbacea: its anticancer potential and responsible constituent(s).International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The subject of this review is the biodiversity of marine sponges and associated microbes which have been reported to produce therapeutically important compounds, along with the contextual information on their geographic distribution. Class Demospongiae and the orders Halichondrida, Poecilosclerida and Dictyoceratida are the richest sources of these compounds. Among the microbial associates, members of the bacterial phylum Actinobacteria and fungal division Ascomycota have been identified to be the dominant producers of therapeutics. Though the number of bacterial associates outnumber the fungal associates, the documented potential of fungi to produce clinically active compounds is currently more important than that of bacteria. Interestingly, production of a few identical compounds by entirely different host-microbial associations has been detected in both terrestrial and marine environments. In the Demospongiae, microbial association is highly specific and so to the production of compounds. Besides, persistent production of bioactive compounds has also been encountered in highly specific host-symbiont associations. Though spatial and temporal variations are known to have a marked effect on the quality and quantity of bioactive compounds, only a few studies have covered these dimensions. The need to augment production of these compounds through tissue culture and mariculture has also been stressed. The reviewed database of these compounds is available at www.niobioinformatics.in/drug.php.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.